JOHN KIRKWOOD to Clinical Trials, Phase III as Topic
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Clinical Trials, Phase III as Topic.
Connection Strength
0.296
-
CTLA-4-blocking immunotherapy with ipilimumab for advanced melanoma. Oncology (Williston Park). 2010 Dec; 24(14):1302, 1304.
Score: 0.088
-
Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy. Clin Cancer Res. 2022 12 01; 28(23):5030-5039.
Score: 0.050
-
Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol. 2000 Nov 15; 18(22):3782-93.
Score: 0.044
-
KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. Future Oncol. 2020 Jan; 16(3):4429-4438.
Score: 0.041
-
Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. Cancer. 2019 01 01; 125(1):18-44.
Score: 0.038
-
Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. J Clin Oncol. 2017 Dec 01; 35(34):3815-3822.
Score: 0.035